ABBV

AbbVie’s Strong Performance: AbbVie is highlighted as a solid dividend stock with a robust business model, showcasing a 9% year-over-year revenue increase to $15.8 billion, driven by key products like Skyrizi and Rinvoq.

Eli Lilly’s Impressive Growth: Eli Lilly has experienced a remarkable 54% year-over-year revenue growth, largely due to its weight loss drug tirzepatide and ongoing diversification into oncology, positioning it well for future success.

Intuitive Surgical’s Competitive Edge: Despite facing challenges from competition and tariffs, Intuitive Surgical maintains a strong market position due to its established da Vinci system, which offers significant pricing power and benefits from increased procedure volumes.

Investment Recommendations: While AbbVie is a strong candidate for income-seeking investors, the Motley Fool's Stock Advisor has identified other stocks as top picks, suggesting potential for higher returns in the coming years.

Stock Performance: AbbVie’s stock (ABBV) has recently slipped below its 50-day simple moving average, indicating short-term weakness, despite a strong long-term trend as it has consistently traded above the 200-day SMA. The stock has risen 26.1% this year, outperforming the industry and the S&P 500.

Impact of Humira's Patent Loss: The decline in sales of AbbVie’s blockbuster drug Humira, due to loss of patent protection and biosimilar competition, has been significant, with sales dropping over 50% in the first nine months of 2025. However, AbbVie has successfully launched new immunology drugs, Skyrizi and Rinvoq, which are expected to drive future growth.

Growth in Other Segments: AbbVie’s oncology and neuroscience segments are showing positive growth, with combined revenues from oncology reaching $5 billion and neuroscience sales increasing by 20.3%. New product launches and approvals in these areas are anticipated to contribute to long-term revenue growth.

Future Outlook: Despite challenges, AbbVie is positioned for continued growth with expectations of mid-single-digit revenue growth in 2025 and a high single-digit CAGR through 2029, driven by strong performance from Skyrizi and Rinvoq. The company has also increased its quarterly cash dividend by 5.5%, reflecting confidence in its financial health.